AMRI to Close Holywell, U.K. API Manufacturing Facility
Complete the form below to unlock access to ALL audio articles.
AMRI has announced that it has decided to close its Holywell, U.K. facility following a consultation process with employee representatives. The Holywell site provides chemical development services and small- and large scale-manufacturing services of active pharmaceutical ingredients (API) and intermediates.
"This was a difficult decision as it impacts team members who have made valuable contributions to AMRI," said William S. Marth, AMRI President and Chief Executive Officer. "We will work diligently to ensure the closing of the Holywell facility goes as smoothly as possible for our customers and employees."
AMRI will transition activities at the Holywell site to other facilities within the AMRI network and plans to cease operations at the site by the end of 2015. Closure of the site is expected to affect approximately 62 positions.
